Q3 EPS Estimate for Core Laboratories Decreased by Analyst

Core Laboratories Inc. (NYSE:CLB) – Equities researchers at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Core Laboratories in a report released on Monday, September 14th. Zacks Research analyst Team now forecasts that the oil and gas company will post earnings of $0.17 per share for the quarter, down from their previous forecast of $0.18. The consensus estimate for Core Laboratories’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories’ Q1 2027 earnings at $0.11 EPS and FY2028 earnings at $1.11 EPS.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company had revenue of $124.61 million for the quarter, compared to analysts’ expectations of $126.26 million. During the same quarter in the previous year, the business posted $0.19 EPS. Core Laboratories’s revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

CLB has been the topic of several other reports. Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Thursday, August 13th. Finally, Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Core Laboratories currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Core Laboratories Stock Down 2.3%

Shares of Core Laboratories stock opened at $12.21 on Tuesday. The company has a 50-day simple moving average of $11.81 and a two-hundred day simple moving average of $13.72. Core Laboratories has a 52-week low of $9.79 and a 52-week high of $20.36. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The stock has a market capitalization of $560.15 million, a PE ratio of 21.80, a price-to-earnings-growth ratio of 2.47 and a beta of 1.08.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Monday, August 10th were given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, August 10th. Core Laboratories’s dividend payout ratio (DPR) is presently 7.14%.

Insider Activity

In other news, CEO Lawrence Bruno purchased 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the purchase, the chief executive officer directly owned 262,438 shares in the company, valued at $2,829,081.64. This trade represents a 1.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Core Laboratories

Several large investors have recently added to or reduced their stakes in the business. Advisors Capital Management LLC bought a new position in Core Laboratories in the second quarter worth approximately $2,766,000. BlackRock Inc. bought a new position in Core Laboratories in the 2nd quarter worth $86,910,000. Heartland Advisors Inc. bought a new position in Core Laboratories in the 2nd quarter worth $12,329,000. Rice Hall James & Associates LLC purchased a new position in Core Laboratories during the second quarter valued at $1,184,000. Finally, Legal & General Group Plc bought a new stake in Core Laboratories during the second quarter valued at about $1,427,000. 97.81% of the stock is currently owned by institutional investors.

About Core Laboratories

Core Laboratories N.V. (NYSE: CLB) is a global provider of reservoir description and production enhancement services for the oil and natural gas industry. The company helps exploration and production companies evaluate subsurface formations, characterize reservoirs and improve the recovery of hydrocarbons from existing fields.

Core Laboratories’ reservoir description activities include laboratory analysis of rock and fluid samples, core analysis, special core analysis, fluid and pressure-volume-temperature studies, geochemical services and related geological and petrophysical evaluations.